Diloxanide

DB08792ExperimentalSmall molecule

Diloxanide (as Diloxanide furoate) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. Although it is not currently approved for use in the... Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.

Mechanism: Unknown. Diloxanide may inhibit protein synthesis.
Curator reviewed
Primary indication: Diloxanide is used alone as a primary agent in the treatment of asymptomatic (cyst passers) intestinal amebiasis caused by Entamoeba histolytica.Curator reviewed
Formula / weight: C₉H₉Cl₂NO₂ · 234.08 g/mol (avg)

Resolves to

Compound

UNII89134SCM7MCAS579-38-4ChEMBLCHEMBL2103768PubChem11367

Clinical / RWD

RxNorm67182ATCP01AB52ATCP01AB53ATCP01AC01PharmGKBPA165958413

Structure

InChIKeyGZZZSOOGQLOEOB-UHFFFAOYSA-NSMILESCN(C(=O)C(Cl)Cl)C1=CC=C(O)C=C1

What you can answer from here — as of February 21, 2021

3ATC codesIncluding every combination product, plus 7 drug categories

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Diloxanide, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account